- Home
- KAPA vs ORGS Comparison
KAPA vs ORGS Comparison
Compare KAPA & ORGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KAPA
- ORGS
- Stock Information
- Founded
- KAPA 2013
- ORGS 2008
- Country
- KAPA United States
- ORGS United States
- Employees
- KAPA N/A
- ORGS N/A
- Industry
- KAPA
- ORGS Biotechnology: Pharmaceutical Preparations
- Sector
- KAPA
- ORGS Health Care
- Exchange
- KAPA NYSE
- ORGS Nasdaq
- Market Cap
- KAPA 21.3M
- ORGS 24.9M
- IPO Year
- KAPA 2024
- ORGS N/A
- Fundamental
- Price
- KAPA $1.45
- ORGS $1.22
- Analyst Decision
- KAPA Strong Buy
- ORGS
- Analyst Count
- KAPA 1
- ORGS 0
- Target Price
- KAPA $9.00
- ORGS N/A
- AVG Volume (30 Days)
- KAPA 203.7K
- ORGS 55.7K
- Earning Date
- KAPA 11-23-2024
- ORGS 11-11-2024
- Dividend Yield
- KAPA N/A
- ORGS N/A
- EPS Growth
- KAPA N/A
- ORGS N/A
- EPS
- KAPA N/A
- ORGS N/A
- Revenue
- KAPA N/A
- ORGS $662,000.00
- Revenue This Year
- KAPA N/A
- ORGS $13,429.43
- Revenue Next Year
- KAPA N/A
- ORGS N/A
- P/E Ratio
- KAPA N/A
- ORGS N/A
- Revenue Growth
- KAPA N/A
- ORGS N/A
- 52 Week Low
- KAPA $1.22
- ORGS $1.93
- 52 Week High
- KAPA $4.00
- ORGS $10.80
- Technical
- Relative Strength Index (RSI)
- KAPA N/A
- ORGS 23.29
- Support Level
- KAPA N/A
- ORGS $2.76
- Resistance Level
- KAPA N/A
- ORGS $3.49
- Average True Range (ATR)
- KAPA 0.00
- ORGS 0.37
- MACD
- KAPA 0.00
- ORGS -0.18
- Stochastic Oscillator
- KAPA 0.00
- ORGS 3.00
About KAPA KAIROS PHARMA LTD
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.
About ORGS Orgenesis Inc.
Orgenesis Inc is a biotech company working to unlock the potential of cell and gene therapies. It is focused on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient for treatment of the patient at the point of care (POCare). The Company's business includes two reporting segments: Octomera and Therapies.